Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: High interleukin-8 (IL-8) levels have been linked to poor prognosis in lung cancer, but conclusive data are lacking.
Materials And Methods: A comprehensive search was conducted on April 1st, 2023, from electronic databases, focusing on studies with IL-8 expression evaluations and the availability of hazard ratio (HR) and 95% confidence intervals (CI) for overall survival (OS), progression-free survival (PFS) and disease-free survival (DFS) or adequate data for their estimation. Then, we examined IL-8 and CXCR1 RNA-seq data from The Cancer Genome Atlas (TCGA) dataset, and we correlated these data with OS.
Results: Among 2655 produced records, 10 manuscripts involving both non-small cell lung cancer and small cell lung cancer, were included in the analysis. Two manuscripts and one study included two and three different cohorts, respectively, for a total of 14 cohorts of patients. Overall, 4 cohorts evaluated IL-8 levels in patients treated with chemotherapy, 3 cohorts immunotherapy, 2 cohorts surgical patients and 4 cohorts other treatments; 1 cohort was removed, as the type of treatments was lacking. The 12 cohorts included in the OS analysis revealed that patients with high IL-8 levels have a lower OS probability, as compared to patients with low IL-8 levels (HR=1.75, 95 % CI 1.36-2.26). No significant difference between patients with high and low IL-8 levels was observed in the 8 cohorts available for PFS analysis. Sensitivity analysis according to treatment revealed significant PFS and OS differences for patients treated with chemotherapy or immunotherapy. Analysis of RNA-seq data from TCGA, confirmed the correlation between high IL-8 and CXCR1 expression and worse OS in patients with resected lung cancer.
Conclusion: To the best of our knowledge, this study represents the first meta-analysis demonstrating a negative prognostic impact of high IL-8 level in lung cancer, particularly in patients treated with chemotherapy and/or immunotherapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.lungcan.2024.107893 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Shenling Baizhu Powder Inhibits Lung Metastasis of Breast Cancer via Regulation of Epithelial-Mesenchymal Transition and Ferroptosis.
Crit Rev Immunol
January 2025
Department of General Surgery, The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300150, China.
Objective: This study aimed to probe the role of Shenling Baizhu powder (SLBZP) in inhibiting breast cancer (BC) lung metastasis, focusing on epithelial-to-mesenchymal transition (EMT) and ferroptosis.
Methods: BC 4T1 cells were treated with low (3.13 µg/mL) and high (12.
Nanomedicine-Mediated Therapies to Target Cancer Stem Cells: An Emerging Technology.
Crit Rev Ther Drug Carrier Syst
January 2025
Department of Biotechnology, School of Chemical and Life Sciences, Jamia Hamdard, New Delhi 110062, India.
Cancer stem cells (CSCs) are a category of cancer cells endowed with the ability to renew themselves, undergo unregulated growth, and exhibit a differentiation capacity akin to that of normal stem cells. CSCs have been linked with tumor metastasis and cancer recurrence due to their ability to elude immune monitoring. As a result, targeting CSCs specifically may improve the efficacy of cancer therapy.
View Article and Find Full Text PDFThe Burden of Cancer and Precancerous Conditions Among Transgender Individuals in a Large Health Care Network: Retrospective Cohort Study.
JMIR Cancer
September 2025
Department of Health Outcomes and Biomedical Informatics, University of Florida, 1889 Museum Road, Suite 7000, Gainesville, FL, 32611, United States, 1 352 294-5969.
Background: Disparities in cancer burden between transgender and cisgender individuals remain an underexplored area of research.
Objective: This study aimed to examine the cumulative incidence and associated risk factors for cancer and precancerous conditions among transgender individuals compared with matched cisgender individuals.
Methods: We conducted a retrospective cohort study using patient-level electronic health record (EHR) data from the University of Florida Health Integrated Data Repository between 2012 and 2023.
Integrated Metabolomics Using Data-Dependent Acquisition and Data-Independent Acquisition and Network Pharmacology to Reveal the Mechanisms of Usnic Acid in Treating Non-Small Cell Lung Cancer.
Chem Biodivers
September 2025
Department of Pharmaceutical Analysis, School of Pharmacy, Hebei Medical University, Shijiazhuang, People's Republic of China.
Usnic acid, a compound from Usneae Filum, has shown notable antitumor effects. Nevertheless, the mechanism of its anti-NSCLC action remains incompletely elucidated. This study used metabolomics, network pharmacology, molecular docking, and dynamics simulation to investigate usnic acid's potential mechanism on NSCLC utilizing A549 cell samples.
View Article and Find Full Text PDFExtracellular Matrix and Fibroblast Activation in Lymphangioleiomyomatosis.
Am J Respir Cell Mol Biol
September 2025
Univ. of Pennsylvania, Medicine, Philadelphia, Pennsylvania, United States.
Lymphangioleiomyomatosis (LAM) is a rare lung disease caused by hyperactivation of the mechanistic/mammalian target of rapamycin 1 (mTORC1) growth pathway in a subset of mesenchymal lung cells. Histopathologically, LAM lesions have been described as immature smooth muscle-like cells positive for the immature melanocytic marker HMB45/PMEL/gp100 and phosphorylated ribosomal protein S6 (pS6). Advances in single cell sequencing (scRNA-seq) technology allowed us to group LAM cells according to their expression of cancer stem cell (CSC) genes and identify three clusters: a high CSC-like state (SLS), an intermediate state, and a low CSC-like inflammatory state (IS).
View Article and Find Full Text PDF